HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Ernst Wolner Anton Moritz Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Podesser, B. K. Articles by Moritz, A. Search for Related Content PubMed PubMed Citation Articles by Podesser, B. K. Articles by Moritz, A.

J Thorac Cardiovasc Surg 1998;115:1121-1129
© 1998 Mosby, Inc.

SURGERY FOR ACQUIRED HEART DISEASE

Long-term results of heart valve replacement with the Edwards Duromedics bileaflet prosthesis: A prospective ten-year clinical follow-up

From the Departments of Cardiothoracic Surgery,^a Medical Statistics,^b and Cardiology,^c all General Hospital, University of Vienna, Vienna, Austria.

Received for publication March 24, 1997. Revisions requested May 15, 1997; revisions received Nov. 5, 1997. Accepted for publication Nov. 14, 1997. Address for reprints: Bruno K. Podesser, MD, Department of Cardiothoracic Surgery, General Hospital, University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

Abstract

Objective: The Edwards Duromedics valve (Baxter Healthcare Corp., Edwards Division, Santa Ana, Calif.) was designed with a self-irrigating hinge mechanism to reduce thromboembolic complications. After good initial clinical results, distribution was suspended in 1988 after reports of valve fracture after 20,000 valves had been implanted. The manufacturer conducted extensive studies to improve the Edwards Duromedics and reintroduced a modified version, which is available as Edwards Tekna. The purpose of the study was the evaluation of long-term results of the original Edwards Duromedics that might be important for the current version, the Edwards Tekna valve.
Methods: A prospective clinical 10-year follow-up was performed of 508 patients who underwent valve replacement with the Edwards Duromedics valve in the aortic (n = 268), mitral (n = 183), and aortic and mitral (n = 56) position.
Results: The perioperative mortality rate was 6.9%; follow-up was 98% complete, comprising 3648 patient-years for a mean follow-up of 86 months (range: 33 to 144 months). The actuarial freedom from complications at the 10-year follow-up and the incidence rate (percent per patient-year) were as follows: late mortality rate, 69.2% ± 2.4% (3.5% per patient-year); thromboembolism, 90.7% ± 1.6% (0.96% per patient-year); anticoagulation-related hemorrhage, 87.7% ± 1.7% (1.34% per patient-year); prosthetic valve endocarditis, 96.7% ± 0.09% (0.38% per patient-year); valve-related mortality rate, 89.3% ± 1.6% (1.21% per patient-year); valve failure, 86.2% ± 1.85% (1.54% per patient-year); and valve-related morbidity and mortality rate, 71.1% ± 2.3% (3.2% per patient-year). Three leaflet escapes were observed (one lethal, two successful reoperations; 99.1% ± 0.05% freedom, 0.08% per patient-year). All patients functionally improved (86% in New York Heart Association classes I and II), and incidence of anemia was insignificant.
Conclusions: These results confirm that the Edwards Duromedics valve shows excellent performance concerning thromboembolism, hemolysis, and functional improvement and will serve as a reference for the last version, the Edwards Tekna valve, where comparable long-term data are currently not available.

This article has been cited by other articles:

				K. Yamazaki, K. Nishimura, A. Iwakura, K. Uehara, T. Okada, and T. Sugita Fracture Embolization of an Edwards-Duromedics Valve with Asymmetrical Closure Asian Cardiovasc Thorac Ann, June 1, 2008; 16(3): 242 - 245. [Abstract] [Full Text] [PDF]

				D. N. Salem, P. T. O'Gara, C. Madias, and S. G. Pauker Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 593S - 629S. [Abstract] [Full Text] [PDF]

				W. T. Smith IV, T. B. Ferguson Jr, T. Ryan, C. K. Landolfo, and E. D. Peterson Should coronary artery bypass graft surgery patients with mild or moderate aortic stenosis undergo concomitant aortic valve replacement?: A decision analysis approach to the surgical dilemma J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1241 - 1247. [Abstract] [Full Text] [PDF]

				D. N. Salem, P. D. Stein, A. Al-Ahmad, H. I. Bussey, D. Horstkotte, N. Miller, and S. G. Pauker Antithrombotic Therapy in Valvular Heart Disease--Native and Prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 457S - 482S. [Abstract] [Full Text] [PDF]

				R. Vink, R. A. Kraaijenhagen, B. A. Hutten, R. B. A. van den Brink, B. A. de Mol, H. R. Buller, and M. Levi The optimal intensity of vitamin k antagonists in patients with mechanical heart valves: A meta-analysis J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2042 - 2048. [Abstract] [Full Text] [PDF]

				P Kvidal, R Bergstrom, T Malm, and E Stahle Long-term follow-up of morbidity and mortality after aortic valve replacement with a mechanical valve prosthesis Eur. Heart J., July 1, 2000; 21(13): 1099 - 1111. [Abstract] [PDF]

				M. E. Mullins, C. L. Brands, and M. R. Daya Unintentional Pediatric Superwarfarin Exposures: Do We Really Need a Prothrombin Time? Pediatrics, February 1, 2000; 105(2): 402 - 404. [Abstract] [Full Text]